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Ischemic stroke is a devastating condition, for which there is still no effective therapy. Acute ischemic stroke 
is associated with high concentrations of glutamate in the blood and interstitial brain fluid. The inability 
of the tissue to retain glutamate within the cells of the brain ultimately provokes neuronal death. Increased 
concentrations of interstitial glutamate exert further excitotoxic effects on healthy tissue surrounding the 
infarct zone. We developed a strategy based on peritoneal dialysis to reduce blood glutamate levels, thereby 
accelerating brain-to-blood glutamate clearance. In a rat model of stroke, this simple procedure reduced the 
transient increase in glutamate, consequently decreasing the size of the infarct area. Functional magnetic res-
onance imaging demonstrated that the rescued brain tissue remained functional. Moreover, in patients with 
kidney failure, peritoneal dialysis significantly decreased glutamate concentrations. Our results suggest that 
peritoneal dialysis may represent a simple and effective intervention for human stroke patients.
Introduction
Stroke is one of the leading causes of death and disability world-
wide, for which no effective neuroprotective therapy exists. Ische-
mic brain damage is triggered by excessive release of the excitatory 
neurotransmitter l-glutamate (1, 2) as a result of energy failure and 
ion gradient collapse, resulting in a reversal of glutamate uptake 
via glutamate transporters (3, 4). Excessive glutamate-evoked Ca2+ 
entry via NMDA receptors further promotes cell death by triggering 
an excitotoxic cascade that involves the activation of Ca2+-depen-
dent enzymes, the disruption of mitochondrial function, and cell 
necrosis or apoptosis (5). Despite intense research efforts, suitable 
pharmacological strategies to enhance neuroprotection of ischemic 
tissues remain elusive (6), partly because pharmacotherapy tends to 
target a single step of the complex excitotoxic cascade and it does 
not distinguish between damaged and healthy tissue.
After acute ischemic stroke, there is an increase in glutamate levels 
in the blood (7), most likely due to enhanced brain-to-blood efflux 
(8, 9) that is driven by increased interstitial glutamate concentrations 
(10). We reasoned that peritoneal dialysis could decrease the blood 
levels of glutamate, thereby minimizing the interstitial glutamate in 
the brain and curtailing ischemia-induced brain damage (8, 9).
Results and Discussion
We investigated the hypothesis that peritoneal dialysis could 
decrease the blood levels of glutamate, thereby minimizing brain 
damage in a model of brain ischemia in which rats were sub-
jected to permanent middle cerebral artery occlusion (pMCAO) 
(Figure 1A). The concentration of glutamate transiently increased 
in plasma 4.5 and 5.5 hours after ischemia (pMCAO; Figure 1B), 
and a corresponding cerebral infarct of 23.3% ± 1.3% (n = 9) was 
observed 24 hours after pMCAO (Figure 1, D and E). Peritoneal 
dialysis is a procedure used to treat patients with severe chronic 
kidney disease, whereby fluids and dissolved substances are 
exchanged between the blood and the dialysate across the peri-
toneum (11, 12). In rats subjected to pMCAO, peritoneal dialysis 
2.5 hours after pMCAO significantly attenuated the increase in 
plasma glutamate induced by ischemia (pMCAO plus dialysis at 
2.5 hours; Figure 1B), and, importantly, this decrease in plasma 
glutamate levels was associated with a significant reduction 
in the volume of cerebral infarct (12.1% ± 2.2%, n = 5, P < 0.001) 
(Figure 1, D and E). Confirming that rat peritoneal dialysis leads 
to a reduction of plasma glutamate, we found that the accu-
mulated glutamate in the dialysate after 1 hour of dialysis was 
59.2 ± 12.2 μM (n = 8). As a control, we added glutamate to the dial-
ysate infusion to cancel the concentration gradient for glutamate, 
therefore preventing its clearance from the blood. Indeed, the addi-
tion of glutamate (400 μM) to the dialysate abolished the glutamate 
clearance observed following peritoneal dialysis, resulting in a sig-
nificant increase in blood glutamate concentration after pMCAO 
(pMCAO plus dialysis at 2.5 hours plus 400 μM glutamate; Figure 
1C) and, importantly, abrogated the beneficial effect of peritoneal 
dialysis on cerebral infarct size (Figure 1D). In sham-operated rats, 
in which middle cerebral arteries were exposed but not occluded, 
no changes in plasma glutamate concentration were detected 
(Figure 1C) and no cerebral infarct was observed (Figure 1D). 
The changes in plasma glutamate correlated well with the size 
of cerebral infarct measured 24 hours after insult (r2 = 0.5312, 
P = 0.0021; Figure 1E). We also observed that peritoneal dialysis 
is equally efficient in reducing the infarct volume when starting 
5 hours after pMCAO (15.0% ± 1.2%, n = 7, P < 0.01; Figure 1, A and D), 
as plasma glutamate at 5.5 hours after pMCAO is still high and 
close to maximal levels (Figure 1B). These data indicate that by 
decreasing the glutamate concentration in the blood, peritoneal 
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dialysis effectively promotes brain-to-blood glutamate efflux (9), 
minimizing the ischemic increase in extracellular glutamate and 
the resulting tissue damage.
Despite the apparent beneficial effects of peritoneal dialysis, it 
remains unclear whether the tissue rescued from death, accord-
ing to structural and anatomical parameters, remains functional. 
To clarify this issue, we used blood oxygenation level–depen-
dent (BOLD) functional magnetic resonance imaging (fMRI) to 
determine tissue functionality (13). fMRI experiments were per-
formed 14 days after the ischemic insult in treated (dialyzed) and 
untreated animals. Electric stimulation of the corpus callosum 
produces widespread fMRI activation maps in the cerebral cor-
tex (Figure 2A). The time course of BOLD signals during callosal 
activation showed fully recovered hemodynamic responses after 
every stimulation epoch and the absence of movement artifacts 
or spontaneous poststimulus activations suggestive of seizures 
(Figure 2E). Functional activation extends to both hemispheres 
almost symmetrically in intact animals (Figure 2A). The symmetry 
was lost in pMCAO animals due to the ischemic injury (Figure 2A). 
To quantify tissue viability, we defined a functionality index as 
the ratio of cortical volume activated in the infarcted hemisphere 
divided by the contralateral (spared) side, during callosal stimula-
tion. Intact animals were used as reference. Thus, the functionality 
index measures the extension of the functional lesion normalized 
to the healthy hemisphere and decreases experimental variability. 
As shown in Figure 2B, pMCAO induced a severe loss of cortical 
viability. Peritoneal glutamate dialysis partially prevented this 
functional damage, rescuing tissue viability (Figure 2B). In the 
same animals, we also measured the infarct size based on the vol-
ume of the T2-hyperintense signal in MRI anatomical scans and 
Figure 1
Peritoneal dialysis attenuates ischemia-induced increases in plasma glutamate concentration and cerebral infarct size. (A) The glutamate 
concentration was determined in plasma samples taken prior to (basal) and at different times (hours) after pMCAO (samples were taken at 
2.5 hours [S2.5], 4.5 hours [S4.5], 5.5 hours [S5.5], and 24 hours [S24]), with peritoneal dialysis initiated 2.5 hours after pMCAO induction. Cere-
bral infarct size was measured 24 hours after pMCAO. Plasma glutamate (normalized to basal levels) and cerebral infarct size were determined 
in the following conditions: (B, D, and E) pMCAO as well as pMCAO plus peritoneal dialysis at 2.5 hours [+dialysis (2.5h)]; (C and D) pMCAO 
plus peritoneal dialysis at 2.5 hours with 400 μM glutamate in the dialysate [+dialysis (2.5h) 400 μM GLU] as well as sham-operated rats (SHAM); 
and (D) pMCAO plus peritoneal dialysis at 5 hours [+dialysis (5h)]. (E) Correlation between plasma glutamate (measured 4.5 hours after pMCAO) 
and infarct size. The average basal glutamate values were 51.8 ± 2.6 μM (n = 21). Data represent the mean ± SEM, and n = 5–9 for each condition. 
*P < 0.05 versus basal values (ANOVA); #P < 0.05, ##P < 0.01, ###P < 0.001 versus corresponding values in pMCAO (ANOVA); &&&P < 0.001 versus 
corresponding values in [+dialysis (2.5h)] (ANOVA).
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were able to demonstrate not only the reduced lesion volume 
under dialysis (Figure 2C), but also a tight correlation between 
the volume of the T2 lesion and the calculated functionality index 
(Figure 2D). As a whole, these findings demonstrate that the 
reduction in infarct volume by dialysis preserves neuronal integ-
rity and confirms the validity of anatomical measures of ischemic 
lesion based on T2-weighted images as predictors of functionality. 
In good agreement with the fMRI results, we were able to demon-
strate that the functionality of the system, measured behaviorally 
using the limb-use asymmetry test, was also largely preserved in 
dialyzed animals (Figure 2F). Taken together, our results indicate 
that the functional deficit produced by ischemic insult can be par-
tially prevented by peritoneal dialysis.
The endothelial cells that form the blood-brain barrier are 
endowed with facilitative and Na+-dependent glutamate trans-
porters in the luminal and abluminal membranes, respectively, 
that mediate glutamate efflux to the blood. Glutamate is actively 
transported from the interstitial space to the endothelial cells and 
Figure 2
Functional recovery of the cerebral cortex.(A) Representative cortical activation during corpus callosum stimulation. fMRI maps are thresholded 
at P < 0.0001 (uncorrected) and overlaid on anatomical scans. Electrode artifact is marked with asterisks, and the arrows point toward the infarct 
area. Color-coded scale represents correlation of the BOLD signal with the stimulation paradigm. Note almost symmetric bilateral activation of the 
cortex in healthy animals upon corpus callosum stimulation. (B) Functionality index measured as the volume of active tissue in the right (ische-
mic) cortex normalized by the left (healthy) cortex. Intact animals (black, n = 3) are used as control for animals subjected to pMCAO (red, n = 5) 
and pMCAO plus peritoneal dialysis at 2.5 hours (blue, n = 7). Signal loss introduced by the implanted electrode (asterisk in A) was corrected. 
Data represent mean ± SEM. (C) Volume of the hyperintense T2-weighted signal (arrows in A). Data represent mean ± SEM. (D) Highly significant 
negative correlation was found between the volume of the ischemic lesion (measured in C) and the functionality index (measured in B). (E) Average 
hemodynamic signal in response to callosal stimulation across all significative voxels in A (P < 0.0001, uncorrected). Stimulation epochs are 
marked by arrowheads. (F) Behavioral testing of the simultaneous use of both forelimbs on cylinder wall during exploratory activity. Data represent 
the mean ± SEM (n = 5–7). Statistical analysis was performed by (B) ANOVA followed by Bonferroni’s test, (C and F) 2-tailed Student’s t test, or 
(D) linear regression. **P < 0.01, ***P < 0.001 control versus pMCAO; ##P < 0.01, ###P < 0.001 pMCAO versus +dialysis (2.5h).
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from the endothelial cells into the circulation via facilitative trans-
porters (8). Peritoneal dialysis is primarily used to treat patients 
with chronic kidney disease (14), which constitute approximately 
15% of all dialysis patients. Thus, to further demonstrate the 
validity of our proposal that peritoneal dialysis promotes brain-to-
blood glutamate efflux, we analyzed serum glutamate concentra-
tions in patients before and after dialysis. One session of peritoneal 
dialysis significantly reduced serum glutamate levels in patients 
with severe chronic kidney disease (Figure 3A). As expected, glu-
tamate rapidly accumulated in the dialysate (58.0 ± 19.5 μM after 
4 hours of dialysis; Figure 3B), almost reaching serum glutamate 
concentrations, indicating that glutamate is rapidly exchanged 
from the blood to the dialysate. These results demonstrate that 
the peritoneum promotes rapid and efficient glutamate exchange 
between the blood and the dialysate and that peritoneal dialysis 
induces rapid clearance of interstitial glutamate. Based on these 
findings, we propose that peritoneal dialysis may offer a suitable 
treatment to decrease blood glutamate concentrations in acute 
stroke patients, efficiently reducing interstitial glutamate levels 
and ultimately ameliorating cerebral damage.
Synaptically released glutamate is nontoxic to neurons because 
its diffusion, binding, and transport via Na+-dependent glutamate 
transporters rapidly lower the concentration of this glutamate to 
concentrations in the submicromolar range, preventing tonic activa-
tion of NMDA receptors (15, 16). By contrast, cerebral ischemia pro-
vokes a more sustained increase in extracellular glutamate concen-
tration (10) that can exert toxic effects on metabolically viable tissue 
around the infarct area (17, 18). Indeed, plasma glutamate concen-
trations remain elevated in patients with progressing ischemic stroke 
24 hours after stroke (7), reflecting the ongoing cell death. Moreover, 
polymorphisms affecting glutamate uptake are associated with ele-
vated levels of plasma glutamate and a poorer neurological outcome 
following stroke (19). Therapeutic interventions based on impeding 
glutamate receptor activation have so far failed to ameliorate tissue 
degeneration after stroke. However, the present findings suggest that 
removing glutamate from the extracellular space may represent an 
effective means of preventing tissue damage surrounding the infarct 
area. Interestingly, decreases in serum glutamate levels induced by 
intravenous injection of oxalacetate and pyruvate (9, 20) also pro-
duce neuroprotection in both focal (21) and global brain ischemia 
(22, 23) and in traumatic brain injury (24). However, undesirable 
side effects of this approach have been reported in vivo, including 
enhanced excitatory transmission in the cortex (25).
Peritoneal dialysis overcomes some of the drawbacks associated 
with the pharmacological neuroprotectants that have failed to 
produce beneficial effects in clinical trials. First, rather than tar-
geting a single step of the complex excitotoxic cascade initiated 
by glutamate (5, 17, 26), peritoneal dialysis removes the source of 
the problem, the interstitial glutamate itself, thereby preventing 
excitotoxicity around the damaged tissue. Second, neuroprotec-
tive drugs do not distinguish between damaged and healthy tissue, 
and, thus, NMDA antagonists will block NMDA receptor–driven 
Ca2+ influx in the infarct area (27) while also altering NMDA recep-
tor–dependent synaptic plasticity in healthy brain regions (28). By 
contrast, the peritoneal dialysis procedure removes interstitial 
glutamate preferentially from the infarct areas that contain the 
higher brain/blood glutamate gradients. Furthermore, the use of 
peritoneal dialysis may substantially reduce the time of treatment.
Most strokes are ischemic and occur after vessel occlusion, while 
about 15% are hemorrhagic in nature. Thrombolysis with recom-
binant tissue plasminogen activator (rtPA) is the only treatment 
approved for reperfusion and reversal of vessel obstruction, although 
in practice this treatment is available to a limited number of patients 
(6). Administration of rtPA requires prior distinction between throm-
botic and hemorrhagic stroke, as this treatment is not suitable for 
hemorrhagic stroke patients. Accordingly, peritoneal dialysis has the 
additional advantage that it is applicable in cases of both ischemic 
and hemorrhagic stroke, as the elevation of interstitial glutamate is 
a feature common to both conditions (29). Other conditions charac-
terized by increases in brain glutamate levels, such as glioma-induced 
seizures (30), may also benefit from this approach. Moreover, perito-
neal dialysis can be implemented rapidly by the nephrologist when 
the patient arrives to hospital. The short time required for catheter 
implantation (15 minutes) ensures that peritoneal dialysis can be 
applied well within the time window for glutamate clearance and for 
therapeutic effect. Finally, the use of peritoneal dialysis for the treat-
ment of stroke would benefit greatly from the widespread experience 
already attained by medical personnel in the use of this technique. 
Nonetheless, preclinical work is needed in order to prove that peri-
toneal dialysis is also effective and safe in aged and/or comorbid ani-
mals, reflecting the clinical situation, and clinical trials are required 
to demonstrate the efficacy of peritoneal dialysis in acute ischemic 
stroke and other brain pathologies.
Methods
Further information is available in the Supplemental Methods (supplemen-
tal material available online with this article; doi:10.1172/JCI67284DS1).
pMCAO. The pMCAO was achieved by ligature as described previ-
ously (31). In sham-operated control rats, the middle cerebral artery was 
exposed but not occluded.
Figure 3
Peritoneal dialysis decreases serum glutamate levels in 
patients with severe chronic kidney disease. (A) Serum glu-
tamate concentration in patients prior to and after one 4-hour 
session of peritoneal dialysis. Glutamate levels were deter-
mined fluorimetrically using glutamate dehydrogenase. The 
serum glutamate concentrations were 109.2 ± 17.6 μM and 
63.6 ± 10.7 μM before and after a 4-hour dialysis session, 
respectively. (B) Time-dependent accumulation of gluta-
mate in the dialysate. The results represent the mean ± SEM 
(n = 7). *P < 0.05 as compared with serum glutamate concen-
tration prior to the dialysis session (Student’s t test).
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